AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2346518
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 mg/day)
Trial: 30794229
Drug: Outpatient physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient physical therapy (outpatient PT)
Trial: 30794229
Drug: Time back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Time back to activities of daily living, time off narcotics
Trial: 28874304
Drug: Cricoid pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cricoid pressure with i-gel
Trial: 28874304
Drug: Sham pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pressure with i-gel
Trial: 25630627
Drug: Atorvastatin dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin dentifrice (2% atorvastatin)
Trial: 23982340
Drug: Tacrolimus QD
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus QD 0.2 mg/kg per day (Arm 2)
Trial: 23982340
Drug: Tacrolimus BD
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus BD 0.2 mg/kg per day (Arm 1)
Trial: 23982340
Drug: Tacrolimus QD
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus QD 0.3 mg/kg per day (Arm 3)
Trial: 23982340
Drug: Tacrolimus QD
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids (Arm 4)
Trial: 20110160
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus qualitative lifestyle (S+L)
Trial: 20110160
Drug: Qualitative lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative lifestyle advice (L)
Trial: 17935515
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% and Vehicle cream (control)
Trial: 11468422
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of SQV SGC twice daily + 100 mg of RTV twice daily (normal breakfast)
Trial: 11468422
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of SQV HGC twice daily + 400 mg of RTV twice daily (normal breakfast)
Trial: 2662837
Drug: Fenoterol syrup
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol syrup (0.25 mg/kg daily dosage)
Trial: 23184737
Drug: Inhaled Fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Fluticasone Furoate (FF) 2000 μg via DISKHALER(®)
Trial: 23184737
Drug: Inhaled Fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Fluticasone Propionate (FP) 1000 μg via DISKHALER(®)
Trial: 18474077
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at a maximum dosage of 1500 mg daily
Trial: 10720048
Drug: Flutamide, testolactone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone
Trial: 22445512
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 mg/d) for 12 weeks
Trial: 15632467
Drug: Ibandronate (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (bolus intravenous injection)
Trial: 9064947
Drug: 24 h
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 h NTG-infusion (group A; 0-24 h saline infusion followed by a 24 h NTG-infusion; n = 16)
Trial: 9064947
Drug: 48 h
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 h NTG-infusion (group B; 0-48 h of NTG-infusion; n = 16)
Trial: 9064947
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (control for group A)
Trial: 9064947
Drug: NTG-infusion (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG-infusion (both groups)
Trial: 1433584
Drug: Random medical
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random medical treatment
Trial: 1433584
Drug: Sideline medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sideline medical treatment
Trial: 6398121
Drug: R 14
RxNorm normalized name: SR 140333
DrugBank: SR 140333 (DB05790)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 14 regimen (cyclophosphamide 2 mg/kg/iv, vincristine 0.01 mg/kg/iv, vinblastine 0.1 mg/kg/iv, 5‐fluorouracil 5 mg/kg/iv, methotrexate 0.7 mg/kg/iv, adriamycin 0.5 mg/kg/iv every 21 days)
Trial: 6398121
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF regimen (cyclophosphamide 100 mg/m2/po, methotrexate 40 mg/m2/iv, 5‐fluorouracil 600 mg/m2/iv)
Trial: 30853809
Drug: Individual computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual computer magnanimous therapy (ic‐mt)
Trial: 30853809
Drug: Group computer
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group computer magnanimous therapy (gc‐mt)
Trial: 27362402
Drug: Imported histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported histamine 1 mg/mL
Trial: 27362402
Drug: Locally-prepared histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally-prepared histamine 1 mg/mL
Trial: 27362402
Drug: Locally-prepared histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally-prepared histamine 5 mg/mL
Trial: 27362402
Drug: Locally-prepared histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally-prepared histamine 10 mg/mL
Trial: 18343177
Drug: L-arginine capsules
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine capsules
Trial: 15963077
Drug: Rifaximin 800
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 800 mg/day
Trial: 12647599
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 to 25 mg/day; n = 15,255)
Trial: 12647599
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg/day; n = 9,048)
Trial: 12647599
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 to 40 mg; n = 9,054)
Trial: 10497444
Drug: Theophylline (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5-20 micrograms/ml)
Trial: 10497444
Drug: Theophylline (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (10-20 micrograms/ml)
Trial: 30907159
Drug: Web-based physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based physiotherapy intervention (twice-weekly sessions)
Trial: 27803231
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dual-antibiotic impregnated cement
Trial: 27803231
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose single-antibiotic impregnated cement
Trial: 24848642
Drug: L‐buthionine sulfoximine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐buthionine sulfoximine (L‐BSO, 20 μM)
Trial: 17046182
Drug: Immediate discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate discontinuation of hormone therapy (n=35)
Trial: 17046182
Drug: Tapered discontinuation
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapered discontinuation of hormone therapy (n=35)
Trial: 16390401
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (amBisome) 50 mg daily
Trial: 16390401
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B (amB) 15 mg daily
Trial: 12926181
Drug: Short-term immunotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term immunotherapy with TA tree pollen and the immunoadjuvant monophosphoryl Lipid A
Trial: 12926181
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension containing 2% tyrosine
Trial: 8535656
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of disease‐modifying antirheumatic drugs (DMARDs)
Trial: 2650722
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2) monthly for up to 5 cycles
Trial: 2650722
Drug: Carboplatin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (400 mg/m2) monthly for up to 5 cycles
Trial: 882723
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg isoproterenol sulfate
Trial: 30052699
Drug: Weekly self-incentivizing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly self-incentivizing (n = 44)
Trial: 30052699
Drug: Monthly self-incentivizing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly self-incentivizing (n = 50)
Trial: 20512497
Drug: Probiotic intervention
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356 for 10 weeks during pollen spread
Trial: 20512497
Drug: Probiotic intervention
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356
Trial: 19332233
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum phosphorus >3.9 mg/dL
Trial: 19332233
Drug: Baseline calcium‐phosphorus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline calcium‐phosphorus product >36.8 mg(2)/dL(2)
Trial: 16846734
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m(2) Days 1 and 8 and paclitaxel 175 mg/m(2) as a 3‐h infusion on Day 1 (GP1)
Trial: 16846734
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and paclitaxel 100 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GP2)
Trial: 16846734
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and docetaxel 40 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GD)
Trial: 12631049
Drug: Carbohydrate-rich drinks
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich drinks (2 x 400 ml)
Trial: 12631049
Drug: Carbohydrate with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate with peptide drinks (2 x 400 ml)
Trial: 3919752
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg of lormetazepam
Trial: 3919752
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg of flunitrazepam
Trial: 29446084
Drug: PP1M (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP1M (50-150 mg-eq)
Trial: 22436170
Drug: Ondasetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondasetron 8 mg iv
Trial: 22436170
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg iv
Trial: 18955908
Drug: Viewing point-light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viewing point-light dot animations of biological motion (specifics on dosage and duration not available)
Trial: 8558750
Drug: Initial bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus dose of 30% rt-PA (41.4 mg) followed by infusion over 60 min
Trial: 8558750
Drug: Initial bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus dose of 10% rt-PA (41.4 mg) followed by infusion over 60 min
Trial: 6452463
Drug: Erythromycin, 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 1.5% topical solution (n = 127)
Trial: 30170024
Drug: Hydrogels (Level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogels (Level 1 - syrup, Level 2 - custard, Level 3 - pudding)
Trial: 26048602
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (5 times per week)
Trial: 26048602
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (3 times per week) + differential training-based occupational therapy (2 times per week)
Trial: 24565295
Drug: Group HDO
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group HDO (ondansetron 8 mg, dexamethasone 8 mg, haloperidol 2 mg)
Trial: 17208898
Drug: ABC/3TC/ZDV (300/150/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/3TC/ZDV (300/150/300 mg) and TDF (300 mg) once daily
Trial: 10834422
Drug: Injected liquid
RxNorm normalized name: Liquid PedvaxHIB Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected liquid silicone (6 injections of 0.2 ml)
Trial: 9663840
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d.
Trial: 9663840
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d.
Trial: 18758356
Drug: Epidural methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural methylprednisolone 40 mg
Trial: 12571466
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg per day for 4 consecutive days once monthly for 6 months, n = 15)
Trial: 12571466
Drug: IVIg (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (800 mg/kg intravenously once monthly for 6 months, n = 8)
Trial: 10850589
Drug: ATG Fresenius
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG Fresenius S (9 mg/kg)
Trial: 8577016
Drug: Structured lipids
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured lipids (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Trial: 8577016
Drug: Long-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain triglycerides (LCT) (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Trial: 3155240
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for the first 10 days of the disease
Trial: 3155240
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of steroids
Trial: 1210468
Drug: Cyclophosphamide (intraarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (intraarticular treatment)
Trial: 28522351
Drug: Early supplemental
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early supplemental parenteral nutrition (PN)
Trial: 26137564
Drug: High-dose patritumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose patritumab
Trial: 26137564
Drug: Low-dose patritumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose patritumab
Trial: 23314982
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (4,000 IU daily for 5 days)
Trial: 23314982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (optimal medical therapy without vitamin D supplementation)
Trial: 21606648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 3,600 mg/day
Trial: 21411701
Drug: Interferon‐α/β receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐α/β receptor expression
Trial: 27945235
Drug: Pretherapeutical Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretherapeutical Hb levels >13.5 g/dl
Trial: 27945235
Drug: Pretherapeutical Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretherapeutical Hb levels <12.7 g/dl and >14.75 g/dl
Trial: 11814373
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation (Group A, n = 70) - 350 mg ferrous sulfate and 1.5 mg folic acid once daily for 90 to 100 days
Trial: 11814373
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation (Group B, n = 67) - same dosage as Group A but administered once a week for 14 weeks
Trial: 2903057
Drug: Intravenous cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide, methotrexate and 5-fluorouracil
Trial: 19195824
Drug: Alumina ceramic-on-ceramic
RxNorm normalized name: ALUMINA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alumina ceramic-on-ceramic (CC)
Trial: 11880817
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and endurance training (CC)
Trial: 10084558
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose short synacthen test (LDSST) - 1 microg tetracosactrin, ACTH-(1-24)
Trial: 10084558
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose short synacthen test (SST) - 250 microg tetracosactrin, ACTH-(1-24)
Trial: 2321994
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% tretinoin solution applied once a day under tape occlusion or twice a day unoccluded for 4 months
Trial: 29252022
Drug: Web-based survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based survey administration (e-mail distribution)
Trial: 29252022
Drug: In-clinic survey
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic survey administration
Trial: 29252022
Drug: Web-based survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based survey administration
Trial: 23281420
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intra-articular morphine
Trial: 23281420
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intra-articular morphine
Trial: 19337769
Drug: Sugar cane
RxNorm normalized name: Sugar cane pollen
DrugBank: Sugarcane (DB10906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar cane policosanols (10 mg/day)
Trial: 12913699
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant hormone therapy (NHT) with 100 mg cyproterone acetate 3 times daily before surgery
Trial: 12913699
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant hormone therapy (NHT)
Trial: 11064528
Drug: Patients' belief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' belief in effective treatments and perceived ability to cope
Trial: 8829026
Drug: Ketoprofen gel
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen gel (2.5% w/w)
Trial: 8829026
Drug: Piroxicam gel
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam gel (0.5% w/w)
Trial: 8829026
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel (1% w/w)